HIV Infection
📧 Sign up to get email alerts when something new happens for HIV Infection.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2016-07-01FDA Approved: EVOTAZ — Supplemental Application (E.R. Squibb & Sons, L.L.C.)
FDA approved a supplemental application for EVOTAZ (atazanavir and cobicistat) to update the product labeling.
-
FDA approval · 2016-06-17FDA Approved: PREZISTA — Supplemental Application (Janssen Products LP)
FDA approved a supplemental application for Prezista (darunavir) from Janssen Products LP.
-
FDA approval · 2016-06-17FDA Approved: PREZISTA — Supplemental Application (Janssen Products LP)
The FDA approved a supplemental application for Prezista (darunavir) submitted by Janssen Products LP. The approval updates the drug's label…
-
FDA approval · 2016-06-17FDA Approved: TYBOST — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for TYBOST (cobicistat) from Gilead Sciences. The submission status was approved.
-
FDA approval · 2016-06-09FDA Approved: TIVICAY — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for TIVICAY (dolutegravir) submitted by ViiV Healthcare Company. This action constitutes a supplemen…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2016-05-20FDA Approved: ETRAVIRINE — Supplemental Application (Patriot Pharmaceuticals)
FDA approves a supplemental NDA for etravirine submitted by Patriot Pharmaceuticals.
-
CLINICAL_TRIALS approval · 2016-04-22Clinical Trial Update: Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)
Marketing approval granted for maraviroc (MK0518) in combination with optimized background antiretroviral therapy for HIV infection.
-
FDA approval · 2016-04-22FDA Approved: TIVICAY — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for TIVICAY (dolutegravir sodium) from ViiV Healthcare Company.
-
FDA approval · 2016-04-21FDA Approved: TRIUMEQ — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for TRIUMEQ (abacavir sulfate, dolutegravir sodium, lamivudine), a fixed-dose combination antiretrov…
-
FDA approval · 2016-04-15FDA Approved: TYBOST — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for TYBOST (cobicistat) submitted by Gilead Sciences, Inc.
-
FDA approval · 2016-04-15FDA Approved: FOSAMPRENAVIR CALCIUM — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved a generic version of fosamprenavir calcium for the treatment of HIV infection, via Mylan's ANDA.
-
FDA approval · 2016-04-11FDA Approved: PREZISTA — Supplemental Application (Janssen Products LP)
FDA approved a supplemental application for Prezista (darunavir) by Janssen Products LP. The approval updates the labeling for the drug.
-
FDA approval · 2016-04-04FDA Approved: DESCOVY — Original Application (Gilead Sciences, Inc.)
FDA approved DESCOVY (emtricitabine and tenofovir alafenamide) as the original application for treatment of HIV-1 infection in adults and ce…
-
FDA approval · 2016-04-01FDA Approved: TRIUMEQ — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for TRIUMEQ (abacavir sulfate, dolutegravir sodium, lamivudine) from ViiV Healthcare Company.
-
FDA approval · 2016-03-31FDA Approved: PREZCOBIX — Supplemental Application (Janssen Products, LP)
The FDA approved a supplemental application for PREZCOBIX (darunavir ethanolate and cobicistat) from Janssen Products, LP.
-
FDA approval · 2016-03-10FDA Approved: VIREAD — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for VIREAD (tenofovir disoproxil fumarate) from Gilead Sciences, Inc.
-
FDA approval · 2016-03-10FDA Approved: ETRAVIRINE — Supplemental Application (Patriot Pharmaceuticals)
FDA approved a supplemental application for ETRAVIRINE submitted by Patriot Pharmaceuticals, leading to changes to the drug's labeling and/o…
-
FDA approval · 2016-03-08FDA Approved: GENVOYA — Supplemental Application (Gilead Sciences, Inc.)
FDA granted supplemental approval for GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide).
-
FDA approval · 2016-03-01FDA Approved: ODEFSEY — Original Application (Gilead Sciences, Inc.)
FDA approved ODEFSEY, a fixed-dose combination oral antiretroviral therapy. It contains emtricitabine, rilpivirine hydrochloride, and tenofo…
-
FDA approval · 2016-02-25FDA Approved: TRUVADA — Supplemental Application (Gilead Sciences, Inc)
FDA approved a supplemental application for TRUVADA (emtricitabine and tenofovir disoproxil fumarate) submitted by Gilead Sciences, Inc.
-
FDA approval · 2016-02-23FDA Approved: COMPLERA — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for COMPLERA, resulting in changes to its labeling.
-
FDA approval · 2016-02-19FDA Approved: STRIBILD — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for STRIBILD, a fixed-dose combination antiviral for HIV-1 infection produced by Gilead Sciences…
-
FDA approval · 2016-02-19FDA Approved: PREZISTA — Supplemental Application (Janssen Products LP)
The FDA approved a supplemental application for PREZISTA (darunavir) by Janssen Products LP.
-
FDA approval · 2016-02-16FDA Approved: VIREAD — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for VIREAD (tenofovir disoproxil fumarate) submitted by Gilead Sciences, Inc.
-
FDA approval · 2016-02-16FDA Approved: VIREAD — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for VIREAD (tenofovir disoproxil fumarate) from Gilead Sciences, Inc., updating its labeling as …